Dataset Information

Dataset of annual metal scrap circularity of titanium industry in China from 2005 to 2020.

ABSTRACT: Titanium products, regarded as a strategic metal by many national governments, play important and irreplaceable roles in national defence and military applications. China has built a large-scale titanium industrial chain, and its status and development pathways will greatly affect the global market. Several researchers contributed a set of reliable statistical data to bridge the knowledge gap in evaluating the industrial layout and the entire structure of China's titanium industry with little literature information regarding the management of metal scrap in the manufacturers of titanium products. To bridge this data gap, we present a dataset of annual metal scrap circularity to uncover China's evolution of the titanium industry today, which contains off-grade titanium sponge, low-grade titanium scrap, and recycled high-grade titanium swarf with the relevant circularity of the titanium industry in China at the national level from 2005 to 2020.

SUBMITTER: Wang W

PROVIDER: S-EPMC10325961 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Dataset of annual metal scrap circularity of titanium industry in China from 2005 to 2020.

Wang Wenhao W Wu Fuzhong F

Scientific data 20230706 1

Titanium products, regarded as a strategic metal by many national governments, play important and irreplaceable roles in national defence and military applications. China has built a large-scale titanium industrial chain, and its status and development pathways will greatly affect the global market. Several researchers contributed a set of reliable statistical data to bridge the knowledge gap in evaluating the industrial layout and the entire structure of China's titanium industry with little li ...[more]

PMID: 37414795

Similar Datasets

Project description:ImportanceOf approximately 9 million patients with cancer in China in 2020, more than half were diagnosed with late-stage cancers. Recent regulatory reforms in China have focused on improving the availability of new cancer drugs. However, evidence on the clinical benefits of new cancer therapies authorized in China is not available.ObjectiveTo characterize the clinical benefits of cancer drugs approved in China, as defined by the availability and magnitude of statistically significant overall survival (OS) results.Design, setting, and participantsThis mixed-methods study comprising a systematic review and cross-sectional analysis identified antineoplastic agents approved in China between January 1, 2005, and December 31, 2020, using publicly available data and regulatory review documents issued by the National Medical Products Administration. The literature published up to June 30, 2021, was reviewed to collect results on end points used in pivotal trials supporting cancer drug approvals.Main outcomes and measuresThe primary outcome measure was a documented statistically significant positive OS difference between a new cancer therapy and a comparator treatment. Secondary outcome measures were the magnitude of OS benefit and other primary efficacy measures in pivotal trials.ResultsBetween 2005 and 2020, 78 cancer drugs corresponding to 141 indications were authorized in China, including 20 drugs (25.6%) (for 30 indications) approved in China only. Of all indications, 26 (18.4%) were evaluated in single-arm or dose-optimization trials, most of which were authorized after 2017. By June 30, 2021, 34 drug indications (24.1%) had a documented lack of OS gain. For 68 indications (48.2%) that had documented evidence of OS benefit, the median magnitude of OS improvement was 4.1 (range, 1.0-35.0) months. After a median follow-up of 1.9 (range, 1.0-11.1) years from approval, OS data for 13 indications (9.2%) were either not reported or were still not mature. Fewer than one-third of cancer drug indications approved in China only had documented evidence of OS benefits (9 of 30 [30.0%]), whereas more than one-half of the cancer drug indications also available in the US or Europe had OS benefits (59 of 111 [53.1%]).Conclusions and relevanceIn this study, almost half of cancer drug indications approved in China had demonstrated OS gain. With the increase of cancer drug approvals based on single-arm trials or immature survival data in recent years, these findings highlight the need to routinely monitor the clinical benefits of new cancer therapies in China.

Dataset Information

Dataset of annual metal scrap circularity of titanium industry in China from 2005 to 2020.

Publications

Dataset of annual metal scrap circularity of titanium industry in China from 2005 to 2020.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets